Professional
Added to YB: 2023-11-15
Pitch date: 2023-11-15
ENZ [bullish]
Enzo Biochem, Inc.
-36.16%
current return
Author Info
1 Main Capital is a long-biased investment partnership that invests primarily in high-quality, attractively valued, growing businesses. Visit their fund website.
Company Info
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally.
Market Cap
$35.7M
Pitch Price
$1.09
Price Target
N/A
Dividend
14.68%
EV/EBITDA
-0.21
P/E
-4.53
EV/Sales
0.07
Sector
Life Sciences Tools and Services
Category
special_situation
1 Main Holdings new position: Enzo Biochem (ENZ)
ENZ: Sold clinical lab biz to LabCorp for $113M ($2.26/share) after cyber breach. Life sci biz worth $50-150M ($1-3/share) on $15-20M gross profit, $5-10M EBITDA. $1.50/share net cash. Activists own ~30%, want to clean up liabilities & sell in 2024. New chair has experience winding down & selling subscale public co's.
Read full article (2 min)